Mifepristone shown more effective than levonorgestrel for emergency contraception

A comprehensive review of 87 clinical trials has found that emergency contraception containing mifepristone is more effective at preventing unintended pregnancies and is associated with fewer side effects than the widely used levonorgestrel‑based pills. The analysis, which evaluated outcomes across diverse populations and dosing regimens, concluded that mifepristone reduces the risk of pregnancy more consistently when administered within the recommended time frame after unprotected intercourse.

The review highlighted that mifepristone, a progesterone receptor antagonist traditionally employed in medical abortions, works by inhibiting implantation and altering the endometrial environment, mechanisms that differ from levonorgestrel’s primarily ovulation‑blocking action. Participants receiving mifepristone reported lower incidences of nausea, headache, and menstrual irregularities, and the drug demonstrated comparable safety profiles across the studies. Researchers noted that while levonorgestrel remains the most accessible option in many regions, the superior efficacy of mifepristone could inform future guidelines and expand contraceptive choices for patients seeking emergency protection.

These findings suggest that incorporating mifepristone into emergency contraceptive protocols may enhance pregnancy prevention outcomes while minimizing adverse effects. Health authorities and clinicians are expected to review the evidence as they consider updates to prescribing practices and public health recommendations.